GLP-1 Receptor Agonists Show No Excess Bowel Obstruction Risk

This large Japanese cohort provides reassurance that initiating glucagon-like peptide-1 receptor agonists does not raise one-year bowel obstruction or ileus risk versus sodium-glucose cotransporter 2 inhibitors, even in higher-risk subgroups.

GLP-1 receptor agonistssemaglutidedulaglutideliraglutideSGLT2 inhibitorsDPP-4 inhibitorstype 2 diabetesbowel obstructionileuspharmacoepidemiologycohort studydrug safety Endocrinology / Diabetes / Obesity

Background Information

GLP-1 receptor agonists show no increased bowel obstruction risk compared to SGLT2 inhibitors.

Patients and clinicians have raised concerns about the risk of bowel obstruction with glucagon-like peptide-1 receptor agonists (GLP-1RAs), impacting treatment choices for type 2 diabetes. In this large database study, GLP-1RA use was not linked to a higher risk of bowel obstruction or ileus compared to sodium-glucose cotransporter 2 inhibitors (SGLT2is), with a hazard ratio of 0.80. The findings reassure clinicians about the gastrointestinal safety of GLP-1RAs compared to SGLT2is for type 2 diabetes, supporting their use without increased concern for bowel obstruction. GLP-1 receptor agonists do not increase bowel obstruction risk versus SGLT2 inhibitors.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Matsuo Y, Okada A, Sakamoto T, Yasunaga H

Citation: Matsuo Y, Okada A, Sakamoto T, et al. Bowel Obstruction/Ileus Associated With the Use of Glucagon-Like Peptide-1 Receptor Agonists: A Nationwide Database Study. Diabetes, obesity & metabolism. 2026. doi:10.1111/dom.71189

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →